The world of pharmacy is at a crossroads, with PharmD graduates pondering their career paths and whether their degree will lead to a fruitful future. A lively discussion on MedBound Hub, initiated by Bhavesh Thakkar, a PharmD graduate, has sparked a debate on whether PharmDs should aim to become the next Medical Science Liaisons (MSLs) instead of traditional clinicians. The conversation, rich with insights from pharmacy professionals and students, sheds light on the evolving roles of PharmDs and the challenges they face in India and beyond.
Bhavesh Thakkar (PharmD graduate) sets the stage by highlighting the growing prominence of the MSL role.
“The role of the Medical Science Liaison (MSL) is booming worldwide. MSLs act as the bridge between pharmaceutical companies and healthcare providers, offering scientific expertise, educating doctors, and influencing prescribing patterns.”Bhavesh Thakkar, Pharm D
This role demands a unique blend of skills, which Bhavesh believes aligns perfectly with the PharmD skill set: “The trend is clear: Pharma industries want professionals with strong drug knowledge + communication skills + clinical understanding. That combination perfectly describes PharmDs.”
However, the question remains why is there a debate about the future of PharmDs if their qualifications seem tailor-made for such roles? The answer lies in the current landscape, particularly in India, where the MSL role and PharmD potential are not fully recognized.
Dr. Deepika Bishnoi, MD in Community Medicine from Mumbai, points out a key issue: “I feel in India, the MSL role is still in its early stages—highly valued by pharma companies but largely invisible to the public.” This lack of visibility and understanding limits the opportunities for PharmDs, who are often overshadowed by clinicians in the race for MSL positions. Anjali, a PharmD graduate, echoes this sentiment: “Right now, in India, PharmDs are not the first preference for medical science liaisons compared to clinicians.”
Despite their extensive training in pharmacology and clinical knowledge, PharmDs struggle to secure roles that fully utilize their expertise.
This raises critical questions about how PharmDs can carve out a sustainable and rewarding career path.
To address these challenges, Kashish Chauhan, a B. Pharm student, proposes a practical solution:
PharmDs should be trained with a dual mindset:
Clinical foundation → so they can provide evidence-based care whenever the system allows them.
Industry readiness → skills in communication, networking, medical writing, and pharma strategy to open global MSL opportunities.
This dual approach ensures that PharmDs are equipped for both clinical and industry roles, making them versatile and competitive in a rapidly evolving job market.
The discussion also prompts a broader question, posed by Bhavesh Thakkar: “Should we stop forcing the clinical dream and instead train PharmDs in medical writing, networking, pharma strategy, and communication? Or should we fight harder to secure prescribing rights and a stronger clinical role in hospitals?” This question encapsulates the dilemma faced by PharmD graduates that whether to pivot toward industry opportunities or continue advocating for clinical recognition.
Prasanth Kumar Choda, B. Pharm, offers a compelling answer: “The solution is balance: train PharmDs in communication and strategy while still pushing for clinical respect. That way, we’re ready for both worlds. The impact depends on how the system evolves, but we deserve more choices and recognition.”
This balanced approach acknowledges the need for PharmDs to adapt to industry demands while continuing to advocate for their rightful place in clinical settings.
For more such interesting pharma-related queries and answers, visit MedBound Hub.